title: Immunotoxins: a promising treatment modality for metastatic melanoma?
abstract: The incidence of melanoma is rising in the Western population, and melanoma is the most aggressive form of skin cancer with a very poor prognosis once it has progressed to metastatic stages. Patients with stage IV melanoma (metastases to distant lymph nodes and other areas of the body) are treated with the chemotherapeutic drug dacarbazine (DTIC). However, fewer than 5% of the patients treated with DTIC sustain long-term complete responses; hence, DTIC is administered with palliative purposes. New therapy is urgently needed. We are developing another therapeutic strategy, specifically targeting melanoma cells with the 9.2.27PE immunotoxin (IT). ITs bind to antigens overexpressed on cancer cells and are therefore tumor selective. This targeted approach may potentially cause fewer side effects in a clinical situation compared to conventional approaches like chemotherapy and radiotherapy.
authors: Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
authors: Karianne
authors: K
authors: Risberg
authors: Oystein
authors: O
authors: Fodstad
authors: Yvonne
authors: Y
authors: Andersson
references: Eur J Cancer. 2004 Nov;40(16):2355-66
references: 15519506
references: PLoS One. 2009 Aug 19;4(8):e6691
references: 19690617
references: Oncogene. 2003 May 19;22(20):3138-51
references: 12789290
references: J Immunol. 2006 Dec 15;177(12):8822-34
references: 17142785
references: J Clin Oncol. 2009 Jun 10;27(17):2823-30
references: 19349552
references: World J Gastroenterol. 2005 Jan 21;11(3):344-7
references: 15637741
references: Int J Cancer. 1992 Oct 21;52(4):631-5
references: 1399146
references: J Cell Biol. 1995 Apr;129(2):309-19
references: 7721936
references: Science. 1996 Feb 23;271(5252):1079-80
references: 8599082
references: Clin Cancer Res. 1997 Mar;3(3):339-45
references: 9815690
references: EMBO J. 1993 Feb;12(2):677-82
references: 8440258
references: Br J Cancer. 2009 Oct 20;101(8):1307-15
references: 19773757
references: Oncology. 2002;62(3):259-68
references: 12065874
references: J Immunother. 2010 Apr;33(3):272-8
references: 20445347
references: Br J Cancer. 2010 Apr 13;102(8):1219-23
references: 20372153
references: Biochem J. 1995 Apr 1;307 ( Pt 1):29-37
references: 7717988
references: Arch Dermatol Res. 2000 May;292(5):225-32
references: 10867810
references: Cancer Res. 1990 Dec 15;50(24):7750-3
references: 2253218
references: Clin Cancer Res. 1995 Dec;1(12):1589-94
references: 9815960
references: Trends Biotechnol. 1998 Dec;16(12):513-20
references: 9881483
references: Proc Natl Acad Sci U S A. 1986 Mar;83(5):1320-4
references: 3006045
references: Expert Opin Pharmacother. 2003 Dec;4(12):2205-11
references: 14640919
references: Bioconjug Chem. 2007 May-Jun;18(3):773-84
references: 17346030
references: Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9514-8
references: 7937798
references: J Biol Chem. 1992 Dec 15;267(35):25396-401
references: 1460035
references: J Natl Cancer Inst. 1986 Dec;77(6):1247-53
references: 3491924
references: Int J Cancer. 2004 Nov 10;112(3):475-83
references: 15382075
references: J Clin Oncol. 2001 May 1;19(9):2370-80
references: 11331315
references: J Clin Oncol. 1996 Jan;14(1):7-17
references: 8558223
references: Mayo Clin Proc. 2006 Apr;81(4):500-7
references: 16610570
references: Nat Med. 1997 Dec;3(12):1362-8
references: 9396606
references: Nat Med. 1996 Mar;2(3):350-3
references: 8612238
references: Neurosurgery. 1997 Nov;41(5):1039-49; discussion 1049-51
references: 9361057
references: J Cutan Pathol. 1983 Aug;10(4):225-37
references: 6350388
references: Crit Rev Immunol. 2004;24(4):267-96
references: 15588226
references: Cancer Treat Rev. 2006 Nov;32(7):524-31
references: 17008014
references: Immunopharmacology. 1997 Oct;37(2-3):117-32
references: 9403331
references: Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11311-6
references: 18678888
references: Clin Cancer Res. 1995 Jan;1(1):57-61
references: 9815887
references: Bacteriol Rev. 1975 Mar;39(1):54-85
references: 164179
references: Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8548-53
references: 10890891
references: J Cell Biol. 1991 Jul;114(2):359-71
references: 1906475
references: Int J Cancer. 2009 Jul 1;125(1):23-33
references: 19350633
references: N Engl J Med. 2006 Jul 6;355(1):51-65
references: 16822996
references: CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
references: 15761078
references: J Immunol. 1992 Sep 15;149(6):2089-94
references: 1517572
references: Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3957-62
references: 10097145
references: Cell. 1987 Jan 16;48(1):129-36
references: 3098436
references: Clin Cancer Res. 2004 Mar 1;10(5):1670-7
references: 15014018
references: AAPS J. 2006 Aug 18;8(3):E532-51
references: 17025272
references: J Immunol. 1985 Jul;135(1):696-702
references: 2582052
references: Mol Cancer. 2010 Feb 03;9:28
references: 20128926
references: Future Oncol. 2009 Aug;5(6):775-8
references: 19663727
references: Exp Cell Res. 2000 Aug 1;258(2):417-24
references: 10896793
references: Melanoma Res. 2008 Apr;18(2):73-84
references: 18337643
references: Med Oncol. 2009;26(3):257-64
references: 19016010